About BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE ...

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals By Formosa Pharmaceuticals Inc. Jun 9, 2025 Updated Jun 9, 2025 ...

TAIPEI, May 7, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc.

Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico ...

APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT ® nanoparticle formulation platform.

APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT ® nanoparticle formulation platform.

APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel ...

Import Item required is betamethasone – 0.95 kg per 1 kg of clobetasol propionate exported. The introduction of this new SION will streamline the process of export for clobetasol propionate by clearly ...

The Directorate General of Foreign Trade (DGFT) has issued a public notice regarding the fixation of a new Standard Input Output Norm (SION) under the Foreign Trade Policy (FTP) -2023. The ...